First Time Loading...

Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 1.32 USD Market Closed
Updated: Apr 29, 2024

Nektar Therapeutics
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nektar Therapeutics
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
Operating Income
-$135.2m
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
-1%
Johnson & Johnson
NYSE:JNJ
Operating Income
$23.4B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$10.8B
CAGR 3-Years
22%
CAGR 5-Years
7%
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Operating Income
$13.1B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
-3%
Merck & Co Inc
NYSE:MRK
Operating Income
$4.1B
CAGR 3-Years
-28%
CAGR 5-Years
-19%
CAGR 10-Years
-7%
Eli Lilly and Co
NYSE:LLY
Operating Income
$10.3B
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
6%

See Also

What is Nektar Therapeutics's Operating Income?
Operating Income
-135.2m USD

Based on the financial report for Dec 31, 2023, Nektar Therapeutics's Operating Income amounts to -135.2m USD.

What is Nektar Therapeutics's Operating Income growth rate?
Operating Income CAGR 10Y
-1%

Over the last year, the Operating Income growth was 44%. The average annual Operating Income growth rates for Nektar Therapeutics have been 29% over the past three years , and -1% over the past ten years .